近期,香港交易所的IPO申请名单中,生物医药企业的身影显著增多,形成了一波引人瞩目的“递表潮”。多家处于不同研发阶段、聚焦肿瘤、自身免疫、细胞基因治疗等领域的生物科技公司,正积极筹备登陆港股市场,寻求资本助力以推进管线研发及商业化进程。Wind数据显示,截至7月9日,今年已有12家生物医药企业成功登陆港交所,分别是脑动极光、大众口腔、维升药业、映恩生物、Mirxes、恒瑞医药、纽曼思、派格生物、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.